Author details

Full Name

Nancy E Davidson

Affiliation

ORCID

Career Start Year

1976

Papers

407

H Index

102

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37480258	Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.		2023
36585450	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.	Nat Cancer	2023
36709040	Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.	Ann Oncol	2023
36493334	Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.	J Clin Oncol	2023
37198173	Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer.	NPJ Breast Cancer	2023
35333494	Cancer Care at the Beginning of the COVID-19 Pandemic: Effects on Patients and Early Interventions to Mitigate Stresses on Care.	Cancer journal (Sudbury, Mass.)	2022
36027481	In It for the Long Haul: Long-Term Benefit With Adjuvant Endocrine Therapy for Premenopausal Women With Early-Stage Steroid Receptor-Positive Breast Cancer.	Journal of Clinical Oncology	2022
35640077	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.	J Clin Oncol	2022
35640075	Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.	J Clin Oncol	2022
36336249	A digital health intervention to improve nutrition and physical activity in breast cancer survivors: Rationale and design of the Cook and Move for Your Life pilot and feasibility randomized controlled trial.	Contemp Clin Trials	2022
35717535	Challenges and opportunities for physician-scientists in advancing cancer research.	Trends Cancer	2022
34362928	Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation.	NPJ Breast Cancer	2021
34183353	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.	Cancer Discov	2021
34076924	Improving Goal Concordant Care Among 10 Leading Academic U.S. Cancer Hospitals: A Collaboration of the Alliance of Dedicated Cancer Centers.	Oncologist	2021
34101813	Selection of Adjuvant Endocrine Therapy for Women With Breast Cancer in Menopausal Transition: Is It Simpler Than We Thought?	Journal of the National Cancer Institute	2021
34324366	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.	J Clin Oncol	2021
33369665	Ki67 Assessment in Breast Cancer: Are We There Yet?	J Natl Cancer Inst	2021
33131319	Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists.	Cancer Investigation	2021
34609096	Updates in endocrine therapy for metastatic breast cancer.	Cancer Biology and Medicine	2021
34543612	Optimal adjuvant endocrine therapy for breast cancer.	Lancet Oncol	2021
33052755	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors.	J Clin Oncol	2020
31996688	Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.	Nat Commun	2020
31917424	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.	JAMA Oncol	2020
32859655	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.	Clinical Cancer Research	2020
31479306	Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update.	J Clin Oncol	2019
31704972	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.	Nat Commun	2019
30452337	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.	J Clin Oncol	2019
30111819	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.	Oncogene	2019
30371813	Gonadotropin-Releasing Hormone (GnRH) Agonists for Fertility Preservation: Is POEMS the Final Verse?	Journal of the National Cancer Institute	2019
30698728	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.	Journal of the National Cancer Institute	2019
31219612	Extending Adjuvant Endocrine Therapy in Breast Cancer: Who, What, Why?	Oncology	2019
29360925	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.	Ann Oncol	2018
28922788	Searching for the IDEAL Duration of Adjuvant Endocrine Therapy.	J Natl Cancer Inst	2018
29863451	Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.	N Engl J Med	2018
30530635	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.	Cancer Prev Res (Phila)	2018
30470782	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.	Scientific Reports	2018
29989839	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary.	J Oncol Pract	2018
30228172	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures.	Cancer Res	2018
29939840	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.	J Clin Oncol	2018
29939838	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.	J Clin Oncol	2018
29388015	Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.	Breast Cancer Research and Treatment	2018
29167860	Incident Cancer in Cancer Survivors-When Cancer Lurks in the Background.	JAMA Oncology	2018
29158255	Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.	Journal of Biological Chemistry	2018
29633255	HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.	International Journal of Cancer	2018
27979914	New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and Other Targeted Therapies.	Clinical Cancer Research	2017
28535794	Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.	Breast Cancer Res	2017
28489980	Practical Approach to Triple-Negative Breast Cancer.	Journal of Oncology Practice	2017
28786414	Breast cancer: What lies beyond APHINITY for HER2-positive breast cancer?	Nature Reviews Clinical Oncology	2017
29138761	A metastasis biomarker (MetaSite <i>Breast</i>â¿¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer.	NPJ Breast Cancer	2017
29137219	Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression.	Oncotarget	2017